(0)
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / April 21, 2021 / At today s AGM of Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, the shareholders of the company approved all motions proposed by the Board of Directors with a very large majority.
In light of the current COVID-19 situation and in line with the applicable Swiss regulation, this year s Annual General Meeting was conducted solely by voting through the independent proxy and without physical attendance of shareholders.
The shareholders of the company elected Agnete Fredriksen and Dominik Höchli as new members of the Board of Directors of Molecular Partners. Both new board members were determined to be independent and add deep scientific and business expertise in immunotherapy, oncology and infectious disease as well as extensive know-how in clinical affairs and marketing to the company, respectively.
Zurich
Züsz
Switzerland
Swiss
Stevenh-holtzman
Vitoj-palombella
Gwen-fyfe
Agnete-fredriksen
Sandip-kapadia
Shai-biran
Seth-lewis
Patrick-amstutz